Cure8 news brief
Long-term control of symptoms and intestinal inflammation is a major need in Crohn's disease. Three-year data showing sustained clinical and endoscopic remission and high rates of steroid-free remission could be meaningful for treatment planning.
Adults with moderately to severely active Crohn's disease, patients on or considering biologic therapy, gastroenterology clinicians, and IBD researchers.
This press release summarizes Week 144 long-term extension data from the GALAXI 2 and 3 Phase 3 studies presented at ACG 2026. Patients received IV induction followed by one of two subcutaneous maintenance regimens (100 mg every 8 weeks or 200 mg every 4 weeks).
The company reports high observed rates of clinical remission, corticosteroid-free remission, and endoscopic remission at three years, and that 74% of TREMFYA-treated patients remained on treatment through three years.
The release is from Johnson & Johnson / PR Newswire and includes standard company framing and an editor’s note about the analysis set and definitions. An investigator quoted in the release is a paid consultant for the company.
If you are considering treatment options, discuss these long-term data with your gastroenterologist; this press release alone does not replace a careful review of the full study reports or independent peer-reviewed publications.
This is a company press release summarizing Phase 3 long-term extension (Week 144) observed data presented at a conference. Observed analyses include only participants who remained on treatment and had Week 144 data; full peer-reviewed publications or regulatory documents should be consulted for complete methods and results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If approved, Tremfya SC induction could provide a fully subcutaneous induction and maintenance option for people with moderately to severely active ulcerative colitis, which may be more convenient than IV induction.
This is a new FDA approval of an IL-23 inhibitor (guselkumab) for adults with moderately to severely active Crohn disease, adding another biologic treatment option. It’s notable because guselkumab offers both IV and...
A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based...
